TABLE 2.
Effect of hepatitis C virus on patient and primary graft survival after alemtuzumab pretreatment versus conventional immunosuppression after follow-up of 13 to 21 monthsa
| Alemtuzumab N=76 | Conventional N=84 | |
|---|---|---|
| Patient survival | ||
| Overall | 64/76 (84%) | 67/84 (80%) |
| Without HCV | 37/38 (97%) | 50/58 (86%) |
| With HCV | 27/38 (71%) | 17/26 (65%) |
| Graft survival | ||
| Overall | 60/76 (79%) | 60/84 (71%) |
| Without HCV | 34/38 (90%) | 46/58 (79%) |
| With HCV | 26/38 (70%) | 14/26 (54%) |
a
A statistical analysis of the effect of HCV on survival and allograft function at the 1-yr milestone is contained in the text.
HCV, hepatitis C virus.